Inmunology

Question 1

Therapeutic antibodies

Cancer therapy

Answer 1

"BART"
Bevacizumab
Alemtuzumab
Rituximab
Transtuzumab

Question 2

Target; CD52

Use: CLL, MS

Answer 2

Alemtuzumab

Question 3

Target: VEGF
Use: colorectal cancer, renal cell cacinoma, non small cell lung cancer

Answer 3

Bevacizumab

Question 4

Target: CD20
Use: B cell-non Hodgkin lymphoma, CLL, ITP, MS, RA

Answer 4

Rituximab

Question 5

Target: HER2
Use: breast cancer, gastric cancer

Answer 5

Trastuzumab

Question 6

Autoinmune disease therapy

Answer 6

Adalimumab
Eculizumab
Ixekizumab
Natalizumab
Ustekinumab

Question 7

Target: soluble TNF-α
Use: IBD, reumatoid arthirtis, ankylosing spondylitis, psoriasis

Answer 7

Adalimumab

Question 8

Target: complement protein C5
Use: PNH

Answer 8

Eculizumab

Question 9

Use: Psoriasis, arthritis psoriatic

Answer 9

Target: IL-17A: Ixekizumab
Target: IL-12/IL-13: Ustekinumab

Question 10

Target: α4-integrin
Use: MS, Chron disease

Answer 10

Natalizumab

Question 11

Antiplatelet agent (IIb/IIIa): prevention in percutaneus coronary intervention

Answer 11

ABCiximab

Question 12

Target: RANKL
Use: osteoporosis

Answer 12

Denosumab

“DENosumab makes bones DENse”

Question 13

Target IgE

Use: refractoy asthma

Answer 13

Omalizumab

Question 14

Target: RSVF protein

Answer 14

Palivizumab

Question 15

Cyclosporine

Answer 15

Inmunosupresants